More than a year has passed since the first confirmed case of coronavirus disease 2019 (COVID-19) was pronounced in Wuhan province, China. The scientific community is focused on several fronts to be able to face the global pandemic caused by this virus. This chapter aims to present an analysis of the latest advances in the fight against the disease through the application of various biotechnological strategies. Results or case reports of various clinical treatments are presented, as well as challenges and perspectives in the reuse of drugs as well as some new strategies including drug mixtures, and natural products such as vitamin D, quercetin, colchicine, vitamin C, and other natural compounds approved by the FDA, and interesting clinical studies carried out in several countries evaluating the efficacy of propolis formulations for the treatment of COVID-19 infection. Furthermore, the results that have been obtained so far with the application of immunization by vaccines are shown, as well as with immunization using neutralizing monoclonals antibodies and their different formulations approved by FDA In summary, this chapter highlights biotechnological development and advancement and the importance of safety aspects and validity of reliable results in this fight against the coronavirus pandemic.
|Title of host publication
|Frontiers of COVID-19
|Subtitle of host publication
|Scientific and Clinical Aspects of the Novel Coronavirus 2019
|Springer International Publishing
|Number of pages
|Published - 1 Jan 2022
Bibliographical notePublisher Copyright:
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.
- Bioactive substances
- Monoclonal antibodies
- Repurposing drugs